Event-Driven Stocks

USANA HEALTH SCIENCES INC

USNANYSE

Healthcare · Medicinal Chemicals & Botanical Products · UT · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs6 gooddetails ↓

Financials

SEC XBRL · annual
 FY26FY24FY23FY22FY21FY19
Revenue$925.3M$854.5M$921.0M$1.19B$1.13B$1.06B
Operating income$37.4M$66.3M$93.1M$170.2M$176.5M$146.2M
Net income$10.8M$42.0M$63.8M$116.5M$124.7M$24.2M
Total assets$742.9M$748.2M$632.8M$577.7M$640.9M$516.9M
Total liabilities$156.6M$161.9M$135.6M
Equity$533.1M$532.1M$497.2M$395.1M$441.6M$351.7M
EPS (diluted)$0.58$2.19$3.30$5.73$5.86$1.01
Shares out.18.5M19.2M19.3M19.3M20.9M23.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2026
Operating margin
4.0%
Net margin
1.2%
Return on equity
2.0%
Return on assets
1.4%
Return on capital (ROCE)
6.1%
Liabilities / assets
21.1%
Debt / equity
0.29×
Book value / share
$28.88
Revenue growth (YoY)
8.3%
Net income growth (YoY)
−74.4%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2026
Altman Z″ (distress)
7.37safe
Accruals / assets
1.6%clean
Piotroski F-Score
7/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
83
/ 100
Profitability 100Growth 50Catalyst 67Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

6 good
  • Operating margin is positive
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
0 acquisitions1 disposalsnet 2,450 shares · last 1
InsiderDateTypeSharesPrice
Fleming John TurmanDirectorJun 1, 2026Sell2,450$17.93

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026595,8524.6+18.7%
Apr 30, 2026501,9165.3+5.0%
Apr 15, 2026477,8794.3-10.1%
Mar 31, 2026531,6233.6+17.2%
Mar 13, 2026453,5712.8+12.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.